Cover Image
市場調查報告書

biOasis Technologies Inc.的產品平台分析

biOasis Technologies Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 320915
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
biOasis Technologies Inc.的產品平台分析 biOasis Technologies Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 31 Pages
簡介

biOasis Technologies Inc.是生物醫藥品企業,從事針對中樞神經系統疾病及障礙的醫藥品·診斷技術之開發與商品化。

本報告提供biOasis Technologies Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

biOasis Technologies Inc.的基本資料

  • biOasis Technologies Inc.概要
  • 主要資訊
  • 企業資料

biOasis Technologies Inc.:R&D概要

  • 主要的治療範圍

biOasis Technologies Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

biOasis Technologies Inc.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

biOasis Technologies Inc.:藥物簡介

  • BT-2111
  • BT-2211
  • MTf-I2S
  • MTfp-I2S
  • Recombinant Enzyme for Hurler Syndrome
  • RNAi Oligonucleotide to Inhibit Nox4 for Central Nervous System Disorders
  • transcend doxorubicin conjugate

biOasis Technologies Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

biOasis Technologies Inc.:最新的開發平台資訊

biOasis Technologies Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07677CDB

Summary

Global Markets Direct's, 'biOasis Technologies Inc. - Product Pipeline Review - 2015', provides an overview of the biOasis Technologies Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of biOasis Technologies Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of biOasis Technologies Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of biOasis Technologies Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the biOasis Technologies Inc.'s pipeline products

Reasons to buy

  • Evaluate biOasis Technologies Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of biOasis Technologies Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the biOasis Technologies Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of biOasis Technologies Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of biOasis Technologies Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of biOasis Technologies Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • biOasis Technologies Inc. Snapshot
    • biOasis Technologies Inc. Overview
    • Key Information
    • Key Facts
  • biOasis Technologies Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • biOasis Technologies Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • biOasis Technologies Inc. - Pipeline Products Glance
    • biOasis Technologies Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • biOasis Technologies Inc. - Drug Profiles
    • BT-2111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BT-2211
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTf-I2S
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTfp-HEXB
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTfp-I2S
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTfp-siRNA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • transcend doxorubicin conjugate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTfp-miRNA
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • biOasis Technologies Inc. - Pipeline Analysis
    • biOasis Technologies Inc. - Pipeline Products by Target
    • biOasis Technologies Inc. - Pipeline Products by Route of Administration
    • biOasis Technologies Inc. - Pipeline Products by Molecule Type
    • biOasis Technologies Inc. - Pipeline Products by Mechanism of Action
  • biOasis Technologies Inc. - Recent Pipeline Updates
  • biOasis Technologies Inc. - Dormant Projects
  • biOasis Technologies Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • biOasis Technologies Inc., Key Information
  • biOasis Technologies Inc., Key Facts
  • biOasis Technologies Inc. - Pipeline by Indication, 2015
  • biOasis Technologies Inc. - Pipeline by Stage of Development, 2015
  • biOasis Technologies Inc. - Monotherapy Products in Pipeline, 2015
  • biOasis Technologies Inc. - Preclinical, 2015
  • biOasis Technologies Inc. - Discovery, 2015
  • biOasis Technologies Inc. - Pipeline by Target, 2015
  • biOasis Technologies Inc. - Pipeline by Route of Administration, 2015
  • biOasis Technologies Inc. - Pipeline by Molecule Type, 2015
  • biOasis Technologies Inc. - Pipeline Products by Mechanism of Action, 2015
  • biOasis Technologies Inc. - Recent Pipeline Updates, 2015
  • biOasis Technologies Inc. - Dormant Developmental Projects,2015
  • biOasis Technologies Inc., Subsidiaries

List of Figures

  • biOasis Technologies Inc. - Pipeline by Top 10 Indication, 2015
  • biOasis Technologies Inc. - Pipeline by Stage of Development, 2015
  • biOasis Technologies Inc. - Monotherapy Products in Pipeline, 2015
  • biOasis Technologies Inc. - Pipeline by Top 10 Target, 2015
  • biOasis Technologies Inc. - Pipeline by Top 10 Molecule Type, 2015
  • biOasis Technologies Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top